Adjuvant Chemotherapy As Postoperative Treatment for High-Risk Stage Ⅰ Endometrial Cancer

燕鑫,高敏,蒋国庆,高雨农,王文,安娜,郑虹

DOI: https://doi.org/10.15932/j.0253-9713.2011.01.031

2011-01-01

Abstract:Objective To assess the efficacy of postoperative adjuvant chemotherapy in patients with International Federation of Gynecology and Obstetrics (FIGO) stage Ⅰ endometrial cancer with high-risk factors for unfavorable prognosis. Methods A retrospective review of 95 FIGO stage Ⅰ endometrial cancer patients treated between 1996 and 2006 in Beijing Cancer Hospital was performed. All patients underwent surgery, of which 20 patients underwent adjuvant chemotherapy. The patients were divided into high-risk and low-risk groups based on the high-risk prognostic factors (non-endometrial adenocarcinoma, tumor grade G3, outer half myometrial invasion, lymph-vascular space involvement). Actuarial techniques were used for the survival and recurrence rates. Results Eight of ten recurrences occurred in patients who did not receive postoperative chemotherapy, in which six were long-term failure. In the remaining two patients who were in the chemotherapy group were pelvic recurrence. Disease recurrence occurred in 4 (16.7%) of 24 high-risk group patients. The 5-year disease-free survival and the 5-year overall survival for the low-risk group were 90.4% and 97.1% respectively, which were 79.5% and 64.9% for the high-risk group (P 0.05, P = 0.005, respectively). Compared to surgery alone, patients with high-risk factors who underwent surgery followed by chemotherapy had a trend to improved 3-year disease-free survival and 3-year overall survival (90.0% vs. 64.8%, 88.9% vs. 83.3%, respectively). Conclusion It is possible that the high-risk FIGO stage Ⅰ endometrial cancer patients should be treated with postoperative adjuvant chemotherapy to decrease long-term failure and improve prognosis.